Israel
A registered CPA with a broad experience in aspects of Nasdaq, IPOs & M&As . Managed financial roles in small and medium sized Pharmaceutical, Biotech, High-Tech and Medical Device companies, both private and public. Currently serves as a strategic and financial advisor of several companies including LiveKidney.Bio and a Board Member of Neurosense Therapeutics LTD. (NASDAQ: NRSN) and My Size, Inc. (NASDAQ: MYSZ). Up to June 2024, I served as the Chief Financial Officer of Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, following its merger with BioSight Ltd., a private pharmaceutical company developing innovative therapeutics for haematological malignancies and disorders, in October 2023, which I led. In 2019, I was appointed as Executive VP and CFO of BioSight Ltd., a role I held until June 2024. In late 2023, I played a major role in the Asset deal between Ayala Pharmaceuticals Inc. and Immunome (Nasdaq: IMNM) until it closed in March 2024. Prior to his time at BioSight, From 2018 to 2019, I served as President and CFO of Exalenz Bioscience Ltd. (TASE: EXEN), a Tel Aviv Stock Exchange listed global, commercial-stage diagnostics company that was later acquired by Meridian Bioscience, Inc. (NASDAQ: VIVO). Prior to that, served as NDRM's CFO, had a pivotal role in their successful IPO, two Follow-On Offerings on Nasdaq and NDRM's acquisition by Mitsubishi Tanabe Pharmaceutical Corporation for a total of US$1.1 billion. I hold an LLM from Bar Ilan University as well as a BA from The College of Management in Rishon LeZion and I am also a licensed CPA.
Redefining medicine through Hybrid Drugs, Remepy is pioneering a new category of therapy by combining pharmaceuticals with targeted digital interventions. Our mission is to deliver more personalized, adaptive, and effective care - helping patients heal through the unified power of biology, behavior, and technology.
LiveKidney is a clinical-stage biotech company that is developing proprietary, pharmaceutical-grade hydrogel-based formulations of Umbilical Cord-derived Mesenchymal Stromal Cells (UC-MSCs) to treat advanced kidney disease and prevent its progression towards kidney failure. The company’s products allow the continuous release of bioactive compounds from the UC-MSCs to the kidneys via unique routes of administration, triggering anti-inflammatory and anti-fibrotic effects. With offices in New York and Tel Aviv, LiveKidney’s delivery platform aims to transform the treatment paradigm for millions of metabolic syndrome and autoimmune patients living with kidney-related diseases.
NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
MySize, Inc. (Nasdaq: MYSZ) is an omnichannel e-commerce platform and provider of AI-driven measurement solutions. The Company’s proprietary measurement technology, combined with products like MySizeID and the recently acquired Naiz Fit, helps retailers drive revenue growth and reduce costs by improving fit accuracy and reducing returns. MySize also operates Orgad, an online retailer platform with expertise in e-commerce, supply chain management, and technology, functioning as a third-party seller on Amazon and other online marketplaces. In addition, MySize has launched innovative retail tools such as the FirstLook Smart Mirror, a mirror-like touch display that enhances in-store shopping experiences and provides contactless checkout.